Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levosimendan→

Levosimendan Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
141505-33-1
Molecular formula
C14H12N6O
Molecular weight
280.28 g/mol
Drug class
Calcium sensitiserinodilator and cardiac inotrope
Mechanism of action
Binds selectively to calcium-saturated cardiac troponin C, increasing myofilament sensitivity to calcium during systole without raising intracellular calcium. It also opens ATP-sensitive potassium channels in vascular smooth muscle, causing arterial and venous vasodilation; PDE3 inhibition may contribute at higher concentrations.
Indications / reported uses
  • Short-term intravenous treatment of acute severe decompensation of chronic heart failure when conventional therapy is insufficient and inotropic support is considered appropriate; use requires specialist haemodynamic monitoring and is product/jurisdiction-specific

Sources: Peer-reviewed review of levosimendan in pulmonary hypertension/right heart failure · Review of levosimendan in heart failure · Product technical sheet (manufacturer; verify local SmPC) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Levosimendan Environmental Risk Assessment (ERA) (the Levosimendan ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.